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Abstract
Background: Iron deficiency prevalence rates frequently exceed 50 % in young children in low-income countries.
The World Health Organization (WHO) recommended universal supplementation of young children where anaemia
rates are >40 %. However, large randomized trials have revealed that provision of iron to young children caused
serious adverse effects because iron powerfully promotes microbial growth. Hepcidin – the master regulator of iron
metabolism that integrates signals of infection and iron deficiency – offers the possibility of new solutions to
diagnose and combat global iron deficiency. We aim to evaluate a hepcidin-screening-based iron supplementation
intervention using hepcidin cut-offs designed to indicate that an individual requires iron, is safe to receive it and
will absorb it.
Methods: The study is a proof-of-concept, three-arm, double blind, randomised controlled, prospective,
parallel-group non-inferiority trial. Children will be randomised to receive, for a duration of 12 weeks, one of
three multiple micronutrient powders (MNP) containing: A) 12 mg iron daily; B) 12 mg or 0 mg iron daily
based on a weekly hepcidin screening indicating if iron can be given for the next seven days or not; C) 6 mg or 0 mg
iron daily based on a weekly hepcidin screening indicating if iron can be given for the next seven days or not. The
inclusion criteria are age 6-23 months, haemoglobin (Hb) concentration between 7 and 11 g/dL, z-scores for Height-
for-Age, Weight-for-Age and Weight-for-Height > -3 SD and free of malaria. Hb concentration at 12 weeks will be used
to test whether the screen-and-treat approaches are non-inferior to universal supplementation. Safety will be assessed
using caregiver reports of infections, in vitro bacterial and P. falciparum growth assays and by determining the changes
in the gut microbiota during the study period.
Discussion: A screen-and-treat approach using hepcidin has the potential to make iron administration safer in areas
with widespread infections. If this proof-of-concept study shows promising results the development of a point-of-care
diagnostic test will be the next step.
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Background
Iron deficiency: global prevalence, health consequences,
and barriers to progress in elimination
Iron deficiency (ID), leading to iron deficiency anaemia
(IDA) and impaired neurocognitive development, remains
the most pervasive nutritional deficiency worldwide [1].
Using currently accepted criteria the prevalence rates for
IDA in young children frequently exceed 50 % in low-
income countries (as is the case in The Gambia) resulting
in impaired immunocompetence and brain development
and thus leading to substantial loss of human potential
[2]. Low cost iron supplements are efficacious in combat-
ting IDA; thus in countries with anaemia rates of >40 %,
WHO recommended universal supplementation of preg-
nant women and young children. However, in 2006, the
Pemba Trial was prematurely terminated due to signifi-
cant increases in the number of serious adverse outcomes
and deaths in young children receiving iron-folic acid
supplements [3]. This result was attributed to a malign
interaction between iron, folic acid and malaria (since a
parallel trial in a non-malarious area of Nepal revealed no
increase in adverse outcomes), and WHO revised its
policy guidance for iron supplementation to a more
cautionary approach in areas with endemic malaria [4].
The new guidelines recommended adoption of targeted
supplementation (a screen-and-treat approach) or the
use of centralized or point-of-use food fortification
using micronutrient powders, which was considered
likely to be a safer option. However, recent studies, in-
cluding a very large trial from a non-malarious area in
Pakistan [5], have revealed important evidence of med-
ically significant adverse outcomes associated with iron
administration. It is assumed that all of these adverse
outcomes may be attributable to host-pathogen compe-
tition for iron whereby supplemental iron has favoured
pathogens more rapidly than their host. Thus there is
an urgent need: a) to understand the pathways by
which provision of iron favours pathogen virulence; and
b) to use this knowledge to design safer modes for pre-
ventative and therapeutic provision of iron to infants
and young children living in infectious environments in
order to reduce infections and to allow maximal brain
development.
Evidence of detrimental effects of iron
Iron is unique among nutrients in being both essential
and highly toxic. This tension has driven the evolution
of complex systems for regulating iron absorption, and
safely chaperoning it during transportation, storage and
utilization in a vast majority of living organisms including
humans of complex systems for regulating iron absorp-
tion, and safely chaperoning it during transport, storage
and utilization [6]. The discovery of the iron-regulatory
hormone hepcidin has thrown a sharp new focus on the
adaptive/protective value of maintaining strict physio-
logical control over iron absorption.
Initially the Pemba results were viewed with some scepti-
cism in many quarters and/or were assumed to only affect
malarious regions, as well as to be confined to supplemen-
tation as opposed to fortification. Yet, additional interven-
tion trials have shown that administration of iron, either
alone or as part of multiple micronutrient formulations,
can lead to serious adverse effects as follows: a) a second
trial in Tanzania showed an association between micronu-
trient supplements containing iron and the risk of malaria
[7]; b) two trials of iron-fortified foods given to children in
Côte d’Ivoire [8] and Kenya [9] caused significant adverse
re-profiling of the gut microflora and evidence of intestinal
inflammation; c) a large cluster-randomized single blind
trial of iron-containing Sprinkles in 17,000+ Pakistani chil-
dren has revealed significant increases in diarrhoea and
pneumonia rates and a very significant increase in severe
and bloody diarrhoea [5]. Finally, a recently published trial
in young Ghanaian children receiving multiple micronu-
trient powders showed a trend towards lower malaria rates
in the group receiving iron but an increase in hospitalisa-
tions among the iron-receiving group [10].
The role of hepcidin – the master regulator of iron
metabolism
Iron homeostasis, and its distribution within the body, is
maintained by regulating absorption of iron through
duodenal enterocytes and by controlling the rate of iron
recycling through macrophages. Hepcidin is a small pep-
tide hormone that binds to and causes the degradation of
ferroportin, an iron export protein highly expressed by
enterocytes and macrophages [11]. High levels of hepcidin
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thereby inhibit absorption of dietary iron and lock iron in
macrophages, rapidly depleting serum iron (causing the
protective hypoferraemia of the acute phase response) and
lowering iron availability for erythropoiesis [12]. An abun-
dance of genetic evidence in humans and experimental
animals indicates that the ferroportin-hepcidin interaction
is the dominant and non-redundant regulator of iron
balance and iron distribution. Regulation of hepcidin is
complex – iron accumulation induces hepcidin, providing
a negative feedback loop to maintain homeostasis, but
hepcidin levels are also increased by inflammatory signals
arising during infections. Iron deficiency and erythropoi-
etic drive suppress hepcidin, releasing iron from cellular
stores and increasing dietary iron absorption. Importantly,
each of these signals is variable, and the balance between
them determines hepcidin synthesis. Thus, an iron defi-
cient individual may have high serum hepcidin due to
an acute infection, but on the other hand severe an-
aemia may suppress hepcidin even in the presence of
inflammation.
Iron redistribution as a component of innate defence
against infection
It is widely accepted that the hypoferraemia of the acute
phase response represents a highly conserved component
of innate defence against a broad-spectrum of extracellular
organisms that could elicit a rapidly fatal septicaemia if
allowed unrestricted access to circulating iron. Several stud-
ies have proposed that iron-requiring intracellular organ-
isms might have evolved their niche specificity precisely to
capitalize upon the consequent iron-rich environment in
macrophages [13]. Such interactions may play a significant
role in explaining susceptibility to secondary infections. Ex-
perimental validation in animal and human studies may
have important therapeutic implications.
Hepcidin-guided iron supplementation
Because hepcidin reports on the balance of iron status and
inflammation, and because hepcidin also determines how
well oral iron is absorbed [11], low hepcidin levels indicate
both a requirement for iron and an ability to utilize it if
provided. Individuals with high hepcidin may be iron re-
plete, or inflamed, or both, but will not be able to absorb
oral iron efficiently. In our recently published paper this is
clearly illustrated in young children, and our results sug-
gest a cut-off of 5.5 ng/mL [14]. As discussed above, iron
supplementation may provide limited benefit and be asso-
ciated with deleterious consequences when given in the
presence of inflammation. Therefore, providing an extra
decision point (do not give iron unless hepcidin is below a
cut-off level) in iron supplementation programs should
make them both safer and more efficient. This will permit
safe iron supplementation of young children in infectious
areas allowing them to reach their full human potential.
Multiple micronutrient powders (MNP)
In this trial we will use a micronutrient powder (MixMe)
as it is used by the United Nations Children’s Fund and
the World Food Programme. In a Cochrane systematic
review (comprising eight large trials from a variety of
settings, including malaria-endemic areas) assessing the
effects and safety of home fortification with multiple
micronutrient powders of foods consumed by children
under two years, anaemia was reduced by 31 % and iron
deficiency by 51 % [15]. The review found no difference
in the effect of the intervention among children living in
malaria endemic areas or areas with sporadic malarial
cases. Based on this review WHO guidelines on home
fortification were developed, strongly recommending
home fortification with micronutrient powders to im-
prove iron status and reduce anaemia among infants and
young children 6-23 months of age [16].
More recently two other trials investigating the effect
of MNP, one in Ghana and one in Pakistan, have been
published. The trial in Pakistan showed significant in-
creases in diarrhoea and bloody diarrhoea and pneumo-
nia rates [5], whereas the trial in Ghana showed a trend
towards lower malaria rates in the group receiving iron
but an increase in hospitalisations among the iron group
[10]. Although our trial will not be powered to assess
morbidity we will monitor our children very closely by
collecting morbidity data twice weekly.
Study objectives
The primary objective is to evaluate whether weekly
hepcidin-based screen-and-treat at 12 mg iron/day, screen-
and-treat at 6 mg iron/day and 12 mg iron/day universal
supplementation for 12 weeks are all non-inferior. The pri-
mary endpoint is Hb (measured using a Medonic haematol-
ogy analyser in the laboratory) at day 84. Secondary
endpoints related to the primary objectives are:
i) Proportion of anaemia (Hb < 11 g/dL) at Day 84;
ii) Proportion of iron deficiency (sTfR/logFerritin
ratio > 3.2 or > 2.0 in the presence of inflammation
(CRP > 5 mg/L) and ferritin < 12 μg/L or < 30 μg/L in
the presence of inflammation) at Day 84;
iii)Proportion of iron deficiency anaemia (Hb <
11 g/dL and sTfR/logFerritin ratio > 3.2 or > 2.0
in the presence of inflammation and ferritin < 12 μg/L
or < 30 μg/L in the presence of inflammation) at Day
84;
iv) Ferritin (only participants without inflammation),
soluble transferrin receptor (sTfR), transferrin and
transferrin saturation (TSAT) at Day 84.
The secondary objectives are the evaluation of i) the
feasibility of adopting a hepcidin-based screen-and-treat
approach to iron supplementation in young children
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(number of weeks supplemented with iron); ii) beneficial
effects with screen-and-treat with respect to maternal
reporting of child illness and safety indices (inflamma-
tory and immune activation markers, faecal gut inflam-
mation markers, gut microbiota, ex-vivo bacterial and P.
falciparum growth); and iii) overall iron absorption over
the 12 week supplementation period in the three study
arms (sub-study).
Methods/design
This paper describes the methodology of a randomized
controlled non-inferiority trial comparing three different
arms. Two arms are screen-and-treat approaches using
hepcidin to indicate whether the body is ready to absorb
iron and thus making it safe to give iron and the third
arm is universal iron supplementation (recommended by
WHO in non-malarial areas). Children randomized to
the universal arm will get 12 mg iron daily for 12 weeks
and children randomized to the screen-and-treat groups
will receive 12 mg or 6 mg iron daily if their weekly hep-
cidin indicates a low value (<5.5 ng/mL), or 0 mg iron if
their hepcidin indicates a high value (≥5.5 ng/mL) for
the next seven days for a total of 12 weeks.
Study site
Study participants will be recruited from 12 communities
in Jarra West (Soma, Karantaba, Kani Kunda, Sankwia,
Mansakonko, Pakalinding, Jenoi and Si Kunda) and Kiang
East (Toniataba, Jiffin, Kaiaf and Genieri), in the Lower
River Region of The Gambia. The communities around
the town of Soma are approximately 170 km east of the
capital Banjul. The town and some of the surrounding
villages have an unreliable electrical power supply. All
communities have access to borehole tap water at central
places. Collected specimen samples will be transported in
cold boxes to the MRC Keneba laboratory in West Kiang,
The Gambia, for laboratory procedures.
Participants
In total 393 healthy young children, aged 6-23 months,
will be identified during child welfare clinics at the
health facilities of Jarra West and Kiang East. After in-
formed consent is obtained, children will have to meet the
inclusion/exclusion criteria to be enrolled into the study.
For inclusion children must be apparently healthy, 6-23
months old, not severely malnourished (z-scores for
Height-for-Age, Weight-for-Age, Weight-for-Height > -3
SD), 7 g/dL ≤Hb < 11 g/dL, free of malaria, resident in the
study area, able and willing to comply with the study
protocol, have no congenital disorders or chronic disease,
not taking regular medication and not participating in an-
other study.
In addition to the main study, ninety children will also
be included into a sub-study (measuring iron absorption).
The differences in the sub-study inclusion criteria are that
eligible children must be aged between 6-8 months and
7 g/dL ≤Hb < 12 g/dL when the stable isotope is adminis-
tered at enrolment.
Study design
This is a proof-of-concept, three-arm, double-blind
randomized controlled non-inferiority trial. The three
arms are:
A) Supplementation with a MNP containing 12 mg iron
daily
B) Supplementation with a MNP containing 12 mg
iron/day if hepcidin is below 5.5 ng/mL, or MNP
containing 0 mg iron/day if hepcidin is ≥ 5.5 ng/mL,
based on a weekly hepcidin screening indicating
whether iron can be given for the next 7 days
C) Supplementation with a MNP containing 6 mg iron/
day if hepcidin is below 5.5 ng/mL, or MNP
containing 0 mg iron/day if hepcidin is ≥ 5.5 ng/mL,
based on a weekly hepcidin screening indicating
whether iron can be given for the next 7 days
Recruitment, enrolment and randomisation
A summary chart of all study procedures is illustrated in
Fig. 1. Mothers/Guardians of the young children identi-
fied during child welfare clinics at the selected health
centres will be visited at home where the study will be
clearly explained. Demographic information will be col-
lected once the child’s mother/guardian has signed the
informed consent form. If the inclusion criteria are met,
the child will be invited for further eligibility screening
during which they will be physically examined. Height,
weight, head circumference, mid-upper arm circumfer-
ence and triceps skinfold thickness will be measured and a
finger prick blood sample for Hb and rapid diagnostic test
(RDT) for malaria will be taken. If Hb is ≥ 7 and < 11 g/dL,
and the RDT is negative, a venous blood sample of 5 mL
will be collected. The mother will then be asked to collect
a stool sample from the child within the next two days.
Enrolled children will be randomized to one of the three
study arms (equal number in each arm) using a block
randomization, balanced by Hb concentration and age, to
minimise potential baseline imbalance.
Children with Hb < 7 g/dL will not be enrolled and will
be referred to the regional health centre for treatment
according to national guidelines. Children with Hb ≥ 11
will not be enrolled as they do not need iron supplemen-
tation. Malaria positive children (positive RDT and con-
firmation by blood film) will not be enrolled and will be
treated according to national guidelines.
The 90 children additionally participating in the sub-
study will be recruited as described above, but the enrol-
ment day procedure is slightly different (Fig. 2). Children
Wegmüller et al. BMC Pediatrics  (2016) 16:149 Page 4 of 9
eligible for the sub-study will not have a venous blood
sample drawn, but will receive the stable isotope dose
on the day of enrolment. They will then be followed up
monthly using a morbidity questionnaire until their par-
ticipation in the main study (earliest seven months after
stable isotope administration). This period is to ensure
that the stable isotope has homogenously equilibrated
with total body iron. On the day of enrolment into the
main study, these children will undergo the same pro-
cedure as described above for the main study.
Recruitment into the sub-study has started in April
2014 while the first cohort for the main study was re-
cruited in May 2014.
Follow-up
Field workers will visit all children daily during the
12 weeks supplementation period in order to supervise
the MNP administration and to check on the children’s
health status. Twice weekly morbidity data (including
questions regarding fever, diarrhoea, vomiting, cough,
any other illness, appetite and any medication taken and
assessment of body temperature) will be captured. If a
child is found unwell, the study nurse will check on the
child and decide on the appropriate treatment. Each
week every child will be screened using a finger prick
blood sample (200 μL) to determine their hepcidin and
Hb level and their malaria status. Hb and RDT testing
will be directly conducted in the field whereas hepcidin
analysis will be performed in the laboratory in Keneba.
On the following day hepcidin results are used to allo-
cate the MNP for the next seven days for each child.
Supervised MNP administration will be conducted by
the field workers daily at participant’s homes. During the
trial, children found with a positive RDT will be further
tested with a blood film and treated according to
national guidelines if malaria is confirmed. Any child
with a Hb < 7 mg/dL will be excluded and referred to
the next health centre for management according to na-
tional guidelines.
On Days 14 and 84 another faecal sample and on Days
49 and 84 another venous blood sample (5 mL) will be
collected, instead of a finger prick blood sample. All
Fig. 1 Main study flow chart. Legend: Hb, Haemoglobin; Fe, Iron; MNP, Micronutrient powder
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blood samples will be kept in a cool chest after collec-
tion and transported to Keneba on ice. An additional
blood sample will be collected on Day 168 from the chil-
dren also participating in the sub-study. Height, weight,
head circumference, mid-upper arm circumference and
triceps skinfold thickness will be re-measured at Days 49
and 84, as well as Day 168 (for the sub-study children).
Investigational product
The investigational product to be used in this trial is a
MNP (MixMe WHO) produced by the DSM Company
and distributed routinely by the United Nations Children’s
Fund and the World Food Programme (contains 10 mg of
iron). For our study purposes the iron concentration will
be altered and we will use products containing 12 mg,
6 mg and 0 mg iron/sachet (daily dose). Each sachet will
consist of the micronutrient powder described in Table 1.
All sachets will look the same, which will help ensure that
field workers, study nurses, participants and the principle
investigator are blinded.
Children additionally participating in the sub-study
will receive a single dose of 2 mg iron, in the form of
57Fe-enriched ferrous sulphate, at the day of enrolment
into the sub-study.
Laboratory evaluations
Blood samples
In the venous blood samples collected on Days 0, 49 and 84
the following parameters will be assessed: full haematology
panel (using a Medonic M20M GP); ferritin, soluble transfer-
rin receptor (sTfR), serum iron, transferrin, transferrin
saturation (TSAT), c-reactive protein (CRP), alpha 1-acid
glycoprotein (AGP) (using a fully automated biochemistry
analyser Cobas Integra 400 plus); and hepcidin (using the
Hepcidin-25 (human) EIA Kit (Bachem) and a Thermo
Scientific Multiskan FC Microplate Photometer). Red blood
cells (RBCs) will be lysed for measurement of riboflavin
status by the erythrocyte glutathione reductase activation
coefficient (EGRAC) test.
Ex vivo growth of P. falciparum will be assessed in
washed RBCs using a field-ready 96-well plate method
and a basic flow cytometry readout (with the BD Accuri
Table 1 Vitamin and mineral content in a single daily dose of
the micronutrient powder (sachet)
Micronutrients Dose/day
Vitamin A (ug RE) 400
Vitamin D (ug) 5
Vitamin E (mg) 5
Vitamin C (mg) 30
Thiamine (B1) (mg) 0.5
Riboflavin (B2) (mg) 0.5
Niacin (B3) (mg) 6
Pyridoxine (B6) (mg) 0.5
Cobalamine (B12) (ug) 0.9
Folate (ug) 150
Iron (encapsulated ferrous fumarate) (mg) 12 or 6 or 0
Zinc (mg) 4.1
Copper (mg) 0.56
Selenium (ug) 17
Iodine (ug) 90
Fig. 2 Sub-study flow chart and timing. Legend: mo, month
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CSampler) in which parasitized RBCs (pRBCs) are iden-
tified by DNA dye SYBR green I (Life Technologies).
Briefly, cultures will be seeded into RBCs from study
participants as rings at 0.5 % initial pRBCs and 1 %
haematocrit in triplicate into 96 well plates and main-
tained for 96 h. Parasite growth rates will be determined
by dividing final parasitaemia at 96 h by initial parasit-
aemia at 0 h [17].
Ex vivo growth of sentinel bacteria (Staphylococcus
aureus, Staphylococcus epidermidis, E. Coli and Salmonella
Typhimurium) in participant serum will be assessed by
optical density plots confirmed by baseline and end-point
colony counts using the cell culture counting facility of
a Thermo Scientific Multiskan FC Microplate Photom-
eter [18].
From the Day 0 whole blood samples genotyping for
haemoglobinopathies will be done using haemoglobin
electrophoresis and DNA will be extracted using the salt-
ing out method to look at genetics of iron metabolism.
Known genetic risk factors to be assessed include alpha-
thalassemia, glucose-6-phosphate dehydrogenase deficiency
and sickle traits. Furthermore, putative functional and key
tagging variants in iron regulatory and inflammatory path-
ways will be screened. Much of this will be available from
the Illumina Infinium Human Exome Bead Chip (Exome
Chip). A specific ‘iron chip’ may be developed.
In addition to all the analyses done with the venous
blood samples for the main study (Days 0, 49 and 84),
the isotopic ratio will be measured in RBCs of sub-study
participants using an Inductively Coupled Plasma Mass
Spectrometer (ICP-MS). In the additional blood sample
taken in this subgroup of participants on Day 168, isotopic
composition, full haematology, ferritin, sTfR, serum iron,
transferrin, TSAT, CRP and AGP will be measured as de-
scribed above.
In the weekly finger prick blood samples Hb using a
HemoCue 301 and a RDT (SD BIOLINE Malaria Ag P.f,
Standard Diagnostics, Inc.) will be directly performed in
the field. In case of a positive RDT a blood film will be
prepared and read at the laboratory in Keneba. Hepcidin
collected into a BD microtainer® will be measured in the
laboratory in Keneba as described above for venous blood.
Stool samples
Samples at Days 0, 14 and 84 will be collected in a sterile
container with a tight, screw top lid that includes an
Anaerocult® sachet (Merck, Darmstadt, Germany) to
create an anaerobic environment. The samples will be
aliquoted and frozen at -20 °C. Calprotectin (fCAL
ELISA, Bühlmann Laboratories AG, Schönenbuch,
Switzerland) will be assessed using ELISA methods.
The gut microbiota composition will be assessed using
16S rRNA analysis and qPCR on enterobacteriaceae
and target commensal bacteria.
Data entry and handling
Field data will be directly entered into handheld de-
vices (Samsung Galaxy Tab 3 SM-T111) using the Cel-
lica Database Software and synced into the database
via a direct secure connection over the 3G mobile net-
work. Field measurements/readings will additionally
be entered into a separate physical data collection
sheet at each measurement station. These data will be
entered by the data entry clerks to serve as the second
entry. A double entry verification system is executed to
detect discrepancies between the two entries. Discrepan-
cies will be sent as queries to the Principal Investigator for
resolution.
Sample size
This is a non-inferiority trial to evaluate efficacy and
the primary endpoint is Hb concentration (measured
using a Medonic haematology analyser in the labora-
tory) at day 84. Based on a SD of 1.15 g/dL of the
mean Hb value of children at 24 week of age, from a
previous trial conducted at Keneba [19], a sample size
of 131 participants in each of the three arms is re-
quired using a 1-sided α of 2.5 and a Bonferroni cor-
rection to adjust for multiple testing. A total sample
size of 393 children followed up for 12 weeks, with a
drop-out of less than 15 %, will provide 80 % power to
establish that:
1) arm B is non-inferior to arm A on the primary
endpoint (Hb concentration at Day 84) defined as
the upper 98.3 % confidence limit for the difference in
mean Hb being not greater than 0.5 g/dL (non-inferiority
margin), the smallest value considered to be of
public health relevance
2) arm C is non-inferior to arm A at the same level as
above
3) arm C is non-inferior to arm B at the same level as
above
For the sub-study, the power calculation for iron
absorption is based on the data from Fomon et al. [20]
in infants. Twenty subjects per group are required to
resolve a difference in absorbed iron of 0.080 mg/d
between the control and intervention period, based on a
SD of 0.13 mg/d (paired t-test). The between group
difference that we estimate being able to resolve is
0.12 mg/d absorbed iron (unpaired t-test). Lower vari-
ability is expected in the calculated kabs values, which
are independent from Hb, body weight, and iron status,
the main contributors to variability in the calculation of
iron absorption. Considering attrition due to the long
time span of at least 7 months between recruitment (ad-
ministration of stable isotope dose) and participation in
the main study, 30 subjects per group will be recruited.
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Statistical analysis
The primary haemoglobin outcome (measured using a
Medonic haematology analyser in the laboratory) at day 84
will be tested for non-inferiority by performing a per-
protocol analysis with a 5 % significance level, adjusted
using the Bonferroni correction to account for three main
comparisons. We will also repeat the main analysis using
the intention-to-treat population as a confirmatory analysis.
Secondary outcome analysis of continuous variables
(ferritin, sTfR, transferrin, TSAT, CRP, AGP, calprotectin,
ex-vivo growth, gut microbiota, number of weeks sup-
plemented) will be done using mixed-effect models with
individuals treated as a random effect, and secondary
outcome analysis of categorical variables (anaemia, ID
and IDA) will be modelled using mixed-effect logistic re-
gression. Interactions between study arm and time in
the study will be investigated.
Morbidity data will be analysed using mixed-effect
models controlled for possible confounders.
Exploratory analysis will be performed using serum iron.
All data will be analysed using Stata v12.1 (StataCorp,
LP, USE, http://www.stata.com) and statistical signifi-
cance will be defined as p < 0.05, unless stated otherwise.
In the sub-study, the linear regression of log57At (57At =
abundance at time t) against time will be calculated for
each subject belonging to the three different groups for the
period of Day 0 to Day 84 (with a midpoint sample at day
49). The slope (kabs) of the regression reflects the absorp-
tion of iron per unit of time. The difference in the slopes
between the groups will be equivalent to the average iron
absorption over time in each group (kabs in groups A, B,
and C, respectively).
The assumption of homogenous labelling will be assessed
by testing the linearity of the slope between Days 0, 49 and
84. In each subject, kabs,i will be calculated from the slope
of the isotopic ratio decrease over the intervention period.
kabs,c will also be calculated for the control period (Day 84
and 168). kabs will be modelled using linear mixed models
with time (intervention and control period) and treatment
as fixed factors and subjects ID as random factors. The
time treatment interaction on kabs will be assessed. A simi-
lar but separate analysis will be conducted on the total
amount of iron absorbed, which will be estimated from the
kabs value in each subject, and the group and time effect
will be modelled with linear mixed models. The models will
be compared to the standard treatment of supplementation
with 12 mg iron/day universal.
Discussion
Prevalence of anaemia is > 50 % and remains a major
public health problem in young children in The Gambia.
Combating anaemia due to iron deficiency is a challenge
due to the potential negative side effects of iron when
given to people with infections, as is common in The
Gambia. The present randomised controlled trial of
screen-and-treat aims to minimise unnecessary exposure
to iron. This will decrease the potential adverse effects
of giving iron at a time when the body can’t utilise it
and will allow maximising the absorption and utilisation
of iron when it is most needed. If a screen-and-treat ap-
proach using a hepcidin cut-off to define ‘ready and safe
to give iron’ is non-inferior to universal supplementa-
tion, then this approach could be used in every health
centre. We hypothesise that the development of a point
of care test, which would immediately tell the nurse/
physician if the person is ready to receive iron, would
make iron administration more targeted and safer.
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